Loading stock data…
$177.62+2.20 (+1.25%)
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Repligen Corporation in the Healthcare sector is trading at $177.62 with a market capitalization of $9.2B. Wall Street consensus targets $196.70 (20 analysts), implying a +10.7% move over the next 12 months. The stock is currently 11% below its 52-week high of $198.87, remaining 23.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $204.13M↑ | $194.25M↓ | $197.91M↑ | $188.81M↑ | $182.37M |
| Gross Profit | $110.04M↑ | $108.28M↑ | $103.83M↑ | $100.52M↑ | $93.00M |
| Operating Income | $19.00M↑ | $17.29M↑ | $16.35M↑ | $12.68M↑ | $8.12M |
| Net Income | $5.01M↓ | $8.33M↓ | $13.29M↓ | $14.91M↑ | $14.87M |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...